Frequently Asked Question The weight loss journey can be confusing
For example, a Cleveland Clinic study from June 2025, involving 7,881 participants, found that high-dose tirzepatide users lost 18.0% of their body weight in one year, semaglutide users lost 13.7%, and those who discontinued early (within three months) lost just 3.6%
But these stories are based on their personal experiences, so it will not always show you how common the symptoms really are
Int Arch Otorhinolaryngol
As personalized medicine advances, GLP-1 agonists may become an integral part of targeted treatment strategies for BBS-related obesity, either alone or in combination with drugs like setmelanotide
Peptides may reduce symptoms while used but don't cure the underlying immune dysregulation